PAVM:NSD-PAVmed Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 6.95

Change

-0.26 (-3.61)%

Market Cap

USD 0.58B

Volume

1.74M

Avg Analyst Target

USD 8.33 (+19.90%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+1.34 (+0.19%)

USD55.06B 79.31 59.42
PODD Insulet Corporation

+0.16 (+0.06%)

USD19.16B 2,202.28 159.45
ABMD Abiomed, Inc

-1.84 (-0.56%)

USD14.83B 66.22 55.76
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-1.72 (-2.08%)

USD12.46B 62.26 31.59
TNDM Tandem Diabetes Care, Inc

-1.63 (-1.53%)

USD6.81B N/A N/A
SWAV ShockWave Medical, Inc

+0.21 (+0.12%)

USD6.37B N/A N/A
IART Integra LifeSciences Holdings ..

-0.37 (-0.52%)

USD6.12B 30.06 26.83
INMD InMode Ltd

+0.38 (+0.33%)

USD4.34B 38.00 31.47
LIVN LivaNova PLC

-4.39 (-5.00%)

USD4.23B 77.40 N/A

ETFs Containing PAVM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 227.83% 99% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 227.83% 99% A+ 98% A+
Trailing 12 Months  
Capital Gain 251.01% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 251.01% 94% A 96% A
Trailing 5 Years  
Capital Gain -54.40% 33% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.40% 33% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 11.34% 33% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.34% 33% F 53% F
Risk Return Profile  
Volatility (Standard Deviation) 82.82% 37% F 21% F
Risk Adjusted Return 13.69% 32% F 31% F
Market Capitalization 0.58B 61% D- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 12.08 23% F 11% F
Price / Cash Flow Ratio -26.29 67% D+ 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -195.44% 11% F 14% F
Return on Invested Capital -220.59% 10% F 2% F
Return on Assets -53.22% 7% F 3% F
Debt to Equity Ratio 15.82% 64% D 64% D
Technical Ratios  
Short Ratio 3.57 51% F 37% F
Short Percent 7.06% 30% F 29% F
Beta 0.32 86% B 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector